



September 14, 2017

To  
The Department of Corporate Services,  
The Bombay Stock Exchange Limited,  
25<sup>th</sup> Floor, Phiroz Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

Dear Sir/Madam,

Attention: Shri. Rakesh Parekh – Special Assistant, Listing Compliance.

**Sub: Discrepancies in Financial Result of the Company for the Quarter ended June 2017 - Gayatri Tissue & Papers Ltd ( 512479 )– Reg.,**


**Ref: Your E- Mail dated 12<sup>th</sup> September, 2017.**

.....  
With reference to your e-mail dated 12th September, 2017 with regard to Discrepancies in Financial Result of the Company for the Quarter ended June 2017, we here by submit the revised Un-Audited Financial Results of the Company for the Quarter ended 30.06.2017.

Kindly acknowledge the receipt of this letter.

Thanking you,

Yours truly,  
For **GAYATRI TISSUE & PAPERS LTD**

  
**(Dinesh Vemula)**  
Company Secretary & Compliance Officer



Regd. Office :  
Gayatri Tissue & Papers Limited  
16/137, No. 5, Near Prabodhan Krida Bhawan,  
Siddhartha Nagar, Goregaon (West), Mumbai 400 104.

Corp Office :  
B1, 6-3-1090, TSR Towers, Raj Bhavan Road,  
Somajiguda, Hyderabad 500 082. A.P.

T +91 40 2331 0330/4284  
F +91 40 2330 8425

www.gtpltd.co.in



## GAYATRI TISSUE & PAPERS LIMITED

Regd. Office:16/137 Siddharthanagar, Road No.5, Near Prabodhan Krida Bhavan, Goregaon(West), MUMBAI-400 104  
UN AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017

CIN: L51900MH1987PLC042141

Rs. In Lakhs

S.No.	Particulars	Quarter ended	Preceding quarter	Quarter ended	Year Ended
		30.06.2017	31.03.2017	30.06.2016	31.03.2017
		Un Audited	Audited	Un Audited	Audited
1	Revenue from operations	120.00	134.12	93.50	415.00
2	Other Income				
3	<b>Total Revenue (1+2)</b>	<b>120.00</b>	<b>134.12</b>	<b>93.50</b>	<b>415.00</b>
4	Expenses:				
	(a) Cost of Materials Consumed	102.77	112.03	85.15	364.86
	(b) Purchase of stock-in-trade				
	(c) Change in Inventories of finished goods, work-in-progress and stock-in-trade				
	(d) Employees benefits expense	4.81	7.49	2.26	14.74
	(e) Finance costs				
	(f) Depreciation and amortisation expenses				
	(g) Manufacturing expenses				
	(h) Research & Development expenses				
	(i) Other Expenditure	5.04	4.68	3.44	11.13
	<b>Total Expenses</b>	<b>112.61</b>	<b>124.20</b>	<b>90.85</b>	<b>390.73</b>
5	<b>Profit before exceptional and extraordinary items and tax (3-4)</b>	<b>7.39</b>	<b>9.92</b>	<b>2.66</b>	<b>24.27</b>
6	Exceptional Items				
7	<b>Profit before extraordinary items and tax (5-6)</b>	<b>7.39</b>	<b>9.92</b>	<b>2.66</b>	<b>24.27</b>
8	Extraordinary Items				
9	<b>Profit before tax (7-8)</b>	<b>7.39</b>	<b>9.92</b>	<b>2.66</b>	<b>24.27</b>
10	Tax Expenses:				
	(1). Current tax	2.28	3.06	0.90	7.50
	(2). Deferred tax				
11	<b>Profit (Loss) for the period from continuing operations (9-10)</b>	<b>5.10</b>	<b>6.86</b>	<b>1.76</b>	<b>16.77</b>
12	Profit/Loss from discontinuing operations				
13	Tax expenses of discontinuing operations				
14	<b>Profit/Loss from discontinuing operations (after tax) (12-13)</b>	-	-	-	-
15	<b>Profit (Loss) for the period (11+14)</b>	<b>5.10</b>	<b>6.86</b>	<b>1.76</b>	<b>16.77</b>
16	<b>Other Comprehensive Income</b>				
16.A	(i). Items that will not be reclassified to profit or loss				
	(ii). Incometax relating to items that will not be reclassified to profit or loss				
16.B	(i). Items that will be reclassified to profit or loss				
	(ii). Incometax relating to items that will be reclassified to profit or loss				
	<b>Total Other Comprehensive Income</b>	-	-	-	-
	<b>Total Comprehensive Income (15+16)</b>	<b>5.10</b>	<b>6.86</b>	<b>1.76</b>	<b>16.77</b>
17	<b>Paid Up Equity Capital</b>	<b>150.00</b>	<b>150.00</b>	<b>150.00</b>	<b>150.00</b>
	(Face Value of the Share )	10.00	10.00	10.00	10.00
18	<b>Earning Per Equity Share (EPS)</b>				
	a) Basic	<b>0.34</b>	<b>0.46</b>	<b>0.12</b>	<b>1.12</b>
	b) Diluted				

**Notes:**



- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 14th August, 2017 and the statutory auditors of the company have carried out limited review of the same.
- The Company is not having any Subsidiary, Joint Venture and Associate, hence no consolidated results are published.
- These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent applicable.

A reconciliation between the profits as reported earlier and the IND AS recast profits for the quarter ended 30th June 2016 is as under:

Particulars	(Rs in Lakhs)
Net profit reported for the quarter ended 30th June, 2016 (published)	1.76
Reclassification of net actuarial gain/loss on employee benefit	-
Deferred tax on above adjustment	-
<b>Net profit recast to Ind AS for the quarter ended 30th June, 2016</b>	<b>1.76</b>

- The company does not have more than one reportable segment. Accordingly, pursuant to (IND AS) 108 on segment reporting issued by the Institute of Chartered Accountants of India, segment information is not required to be provided.
- There are no investor complaints pending at the beginning and end of the quarter. The company did not receive any investor complaints during the quarter.
- Previous year / quarter figures have been re-grouped and recasted wherever necessary.

Place: Hyderabad,  
Date: 14.08.2017

  
  
**(P. MARUTHI BABU)**  
 Executive Director



**Limited Review Report**

**To**  
**The Board of Directors**  
**M/s. Gayatri Tissue and Papers Limited.**

We have reviewed the accompanying statement of unaudited financial results of M/s. Gayatri Tissue and Papers Limited for the period ended 30.06.2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For VAS & Co.**  
Chartered Accountants  
Firm's Registration Number: 004537S

**(G. S. Srinivas)**  
Proprietor  
Membership No.020901

Place of Signature: Hyderabad  
Date: 14.08.2017